Eli Lilly and WuXi AppTec contributed to what was reportedly a down round for T-cell oncology treatment developer Immunocore following a $320m raise in 2015.
Immunocore, UK-based biopharmaceutical medicine developer with roots at University of Oxford, closed a $130m series B round featuring pharmaceutical firms Eli Lilly and WuXi AppTec yesterday, the latter through its corporate venturing fund.
Growth equity firm General Atlantic led the round, which featured CCB International, JDRF T1D Fund, Rock Springs Capital, Terra Magnum Capital Partners and five existing shareholders that included Eli Lilly and RTW Investments.
Bill & Melinda Gates Foundation also participated in the round, transforming convertible…